ISRCTN14340698已完成1 期
Phase I trial: Labcorp Drug Development Study: 8479217 [The full scientific title will be published within 30 months after the end of the trial]
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
不适用
A Phase I, open-label trial to investigate pharmacokinetics, safetyand tolerability of TMC125 at steady-state in treatment-experiencedHIV-1 infected children.HIV-1MedDRA version: 8.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2006-002183-26-DETibotec Pharmaceuticals Ltd40
进行中（未招募）
1 期
A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.EUCTR2006-002183-26-GBTibotec Pharmaceuticals Ltd42
已完成
1 期
Phase 1 trial: Labcorp code 8501022Healthy volunteersISRCTN13265717Albireo (Sweden)76
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
招募中
不适用
A Phase 1 trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.relapsed or refractory lymphoid malignancy, relapsed/refractory multiple myeloma, relapsed/refractory Hodgkins lymphoma, relapsed/refractory peripheral T-cell lymphoma, relapsed/refractory cutaneous T-cell lymphoma, subtypes mycosis fungoides and Sézary syndrome, relapsed/refractory T-cell Prolymphocytic leukemia. Note: Recruitment to the CTCL and T-PLL cohorts was halted on 01 March 2021.Relapsed/ refractory Hematologic Malignancies10025319NL-OMON52700Mundipharma Research Limited10